Lactobacillus crispatus M247 oral administration: Is it really an effective strategy in the management of papillomavirus-infected women?
HPV infection
Lactobacillus crispatus M247
Microbiota
Papillomaviridae
Probiotics
Uterine cervical neoplasms
Journal
Infectious agents and cancer
ISSN: 1750-9378
Titre abrégé: Infect Agent Cancer
Pays: England
ID NLM: 101276559
Informations de publication
Date de publication:
21 Oct 2022
21 Oct 2022
Historique:
received:
23
03
2022
accepted:
28
09
2022
entrez:
22
10
2022
pubmed:
23
10
2022
medline:
23
10
2022
Statut:
epublish
Résumé
Recent studies have shown the importance of the microbiota in women's health. Indeed, the persistence of Human Papilloma Virus (HPV)-related lesions in patients with dysbiosis can be the antechamber to cervical cancer. The aim of this study was to evaluate whether long term administration of oral Lactobacillus crispatus can restore eubiosis in women with HPV infections and hence achieve viral clearance. In total, 160 women affected by HPV infections were enrolled at the Department of Gynecological Obstetrics of "San Paolo" Hospital, Italy between February 2021 and February 2022. The women were randomly assigned to two groups, one in treatment with oral Lactobacillus crispatus M247 (group 1, n = 80) versus the control group, that hence only in follow-up (Group 2, n = 80). After a median follow-up of 12 months (range 10-30 months), the likelihood of resolving HPV-related cytological anomalies was higher in patients in treatment with the long term oral probiotic (group 1) versus the group that perfom only follow-up (group 2) (60.5% vs. 41.3%, p = 0.05). Total HPV clearance was shown in 9.3% of patients undergoing only follow-up compared to 15.3% of patients in the group taking long term oral Lactobacillus crispatus M247 (p = 0.34). However, the percentage of HPV-negative patients, assessed with the HPV-DNA test, documented at the end of the study period was not significantly different from the control group. Despite the limitations of our analysis, we found a higher percentage of clearance of PAP-smear abnormalities in patients who took long term oral Lactobacillus crispatus M247 than in the control group. Larger studies are warranted, but we believe that future research should be aimed in this direction. Trial registration This study is retrospectively registered.
Sections du résumé
BACKGROUND
BACKGROUND
Recent studies have shown the importance of the microbiota in women's health. Indeed, the persistence of Human Papilloma Virus (HPV)-related lesions in patients with dysbiosis can be the antechamber to cervical cancer. The aim of this study was to evaluate whether long term administration of oral Lactobacillus crispatus can restore eubiosis in women with HPV infections and hence achieve viral clearance.
METHODS
METHODS
In total, 160 women affected by HPV infections were enrolled at the Department of Gynecological Obstetrics of "San Paolo" Hospital, Italy between February 2021 and February 2022. The women were randomly assigned to two groups, one in treatment with oral Lactobacillus crispatus M247 (group 1, n = 80) versus the control group, that hence only in follow-up (Group 2, n = 80).
RESULTS
RESULTS
After a median follow-up of 12 months (range 10-30 months), the likelihood of resolving HPV-related cytological anomalies was higher in patients in treatment with the long term oral probiotic (group 1) versus the group that perfom only follow-up (group 2) (60.5% vs. 41.3%, p = 0.05). Total HPV clearance was shown in 9.3% of patients undergoing only follow-up compared to 15.3% of patients in the group taking long term oral Lactobacillus crispatus M247 (p = 0.34). However, the percentage of HPV-negative patients, assessed with the HPV-DNA test, documented at the end of the study period was not significantly different from the control group.
CONCLUSIONS
CONCLUSIONS
Despite the limitations of our analysis, we found a higher percentage of clearance of PAP-smear abnormalities in patients who took long term oral Lactobacillus crispatus M247 than in the control group. Larger studies are warranted, but we believe that future research should be aimed in this direction. Trial registration This study is retrospectively registered.
Identifiants
pubmed: 36271433
doi: 10.1186/s13027-022-00465-9
pii: 10.1186/s13027-022-00465-9
pmc: PMC9587645
doi:
Types de publication
Journal Article
Langues
eng
Pagination
53Informations de copyright
© 2022. The Author(s).
Références
J Natl Cancer Inst. 2008 Apr 2;100(7):513-7
pubmed: 18364507
Carcinogenesis. 2010 Nov;31(11):1905-12
pubmed: 20819779
BMC Infect Dis. 2018 Jan 5;18(1):13
pubmed: 29304768
J Prev Med Hyg. 2010 Dec;51(4):139-45
pubmed: 21553558
Anaerobe. 2010 Jun;16(3):210-5
pubmed: 19925874
Obstet Gynecol. 2012 Jul;120(1):166-72
pubmed: 22914406
Proc Natl Acad Sci U S A. 1977 Nov;74(11):5088-90
pubmed: 270744
Ann Biol Clin (Paris). 2016 Aug 1;74(4):421-7
pubmed: 27492695
Future Microbiol. 2011 May;6(5):567-82
pubmed: 21585263
JAMA. 2002 Apr 24;287(16):2114-9
pubmed: 11966386
BMC Infect Dis. 2012 Feb 08;12:33
pubmed: 22316377
Microbiome. 2016 Nov 1;4(1):58
pubmed: 27802830
Medicine (Baltimore). 2020 Sep 25;99(39):e22146
pubmed: 32991408
Probiotics Antimicrob Proteins. 2018 Jun;10(2):236-242
pubmed: 29071554
Infect Dis Obstet Gynecol. 1996;4(1):2-6
pubmed: 18476056
BMC Infect Dis. 2013 Jan 26;13:43
pubmed: 23351177
PLoS One. 2013 May 22;8(5):e63514
pubmed: 23717441
Am J Obstet Gynecol. 2001 Aug;185(2):375-9
pubmed: 11518895
J Clin Pathol. 2002 Apr;55(4):244-65
pubmed: 11919208
Int J Mol Sci. 2020 May 04;21(9):
pubmed: 32375324
AMB Express. 2019 Mar 23;9(1):40
pubmed: 30904962
Cancer Cytopathol. 2015 May;123(5):271-81
pubmed: 25931431
Cancer Res Treat. 2018 Jul;50(3):813-822
pubmed: 28814070
BMC Cancer. 2018 Mar 23;18(1):318
pubmed: 29566658
J Cancer Res Clin Oncol. 2020 Mar;146(3):647-657
pubmed: 32006118
Microbes Infect. 2006 May;8(6):1450-4
pubmed: 16697231
Biology (Basel). 2022 Jul 26;11(8):
pubmed: 35892970
Medicine (Baltimore). 2021 Feb 5;100(5):e24485
pubmed: 33592901
Nutr Cancer. 2012;64(7):1103-11
pubmed: 23061912
Arch Gynecol Obstet. 2017 Jan;295(1):197-203
pubmed: 27619686
Medicina (Kaunas). 2020 Feb 22;56(2):
pubmed: 32098430
J Physiol Pharmacol. 2009 Dec;60 Suppl 6:19-26
pubmed: 20224147
Cell Microbiol. 2008 Jul;10(7):1442-52
pubmed: 18331465
Gynecol Oncol. 2019 Nov;155(2):237-244
pubmed: 31500892
J Pers Med. 2022 Aug 26;12(9):
pubmed: 36143172
BMC Infect Dis. 2015 Mar 04;15:115
pubmed: 25879811
PLoS One. 2012;7(10):e45201
pubmed: 23056195
Crit Rev Oncol Hematol. 2020 Jul;151:102981
pubmed: 32485429
Front Oncol. 2020 Jun 04;10:1009
pubmed: 32656087
J Med Virol. 2009 Mar;81(3):529-35
pubmed: 19152401
BMC Med. 2021 Sep 10;19(1):205
pubmed: 34503502
Infez Med. 2017 Sep 1;25(3):247-257
pubmed: 28956542
Food Chem Toxicol. 2011 Apr;49(4):770-9
pubmed: 21130831
Int J Mol Sci. 2019 Dec 10;20(24):
pubmed: 31835581